The 29 references in paper O.  Shakhmatova O., A. Komarov L., О. Шахматова О., А. Комаров Л. (2018) “ПРАСУГРЕЛ В ЛЕЧЕНИИ ПАЦИЕНТОВ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ И ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВОМ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ // PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM” / spz:neicon:aterotromboz:y:2018:i:1:p:52-66

1
Farid nA, Kurihara A, Wrighton sA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol, 2010, 50: 126–142. doi: 10.1177 / 0091270009343005.
(check this in PDF content)
2
o’Gara Pt, Kushner FG, Ascheim DD et al. 2013 ACCF / AHA Guideline for the Management of st‑elevation Myocardial Infarction. Circulation, 2013, 127: e362‑e425.
(check this in PDF content)
3
Ibanez B, James s, Agewall s et al. esC scientific Document Group, 2017 esC Guidelines for the man‑ agement of acute myocardial infarction in patients presenting with st‑segment elevation: the task Force for the management of acute myocardial infarction in patients presenting with st‑segment elevation of the european society of Cardiology (esC). european Heart Journal, 2018 January 7, 39 (Issue 2): 119–177. https: //doi.org / 10.1093 / eurheartj / ehx393.
(check this in PDF content)
4
Amsterdam eA, Wenger nK, Brindis RG et al. 2014 AHA / ACC Guideline for the Management of Patients With non – st‑elevation Acute Coronary syndromes: executive summary. Circulation, 2014, 130: 2354–2394.
(check this in PDF content)
5
Roffi M, Patrono C, Collet J‑P et al. 2015 esC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st‑segment elevation: task Force for the Management of Acute Coronary syndromes in Patients Presenting without Persistent st‑segment elevation of the european society of Cardiology (esC). european Heart Journal, 2016 January14, 37 (Issue 3): 267–315. https: //doi. org / 10.1093 / eurheartj / ehv320.
(check this in PDF content)
6
Valgimigli M, Bueno H, Byrne RA et al. 2017 esC focused update on dual antiplatelet therapy in coro‑ nary artery disease developed in collaboration with eACts. european Heart Journal, 2017, 0: 1–48. doi: 10.1093 / eurheartj / ehx419.
(check this in PDF content)
7
Wiviott sD, Braunwald e, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. n engl J Med, 2007, 357 (20): 20 01– 2015.
(check this in PDF content)
8
Wilcox R, Iqbal K, Costigan t et al. An analysis of tRIton‑tIMI 38, based on the 12 month recom‑ mended length of therapy in the european label for prasugrel. Curr Med Res opin, 2014, 30: 2193–205. doi: 10.1185 / 03007995.2014.944638.
(check this in PDF content)
9
Montalescot G, Bolognese L, Dudek D et al. ACCoAst Investigators. Pretreatment with prasugrel in non‑st‑segment elevation acute coronary syn‑ dromes. n engl J Med, 2013, 369: 999–1010. doi:
(check this in PDF content)
10
1056 / neJMoa1308075. 10. Antman eM, Wiviott sD, Murphy sA et al. early and late benefits of Prasugrel in patients with acute coronary syndromes undergoing percutaneous coro‑ nary intervention: a tRIton‑tIMI 38 (tRial to assess Improvement in therapeutic outcomes by optimizing platelet Inhibition with Prasugrel‑thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol, 2 0 0 8 , 51 (21 ): 2028–2033.
(check this in PDF content)
11
Angiolillo DJ, Rollini F, storey RF et al. International expert Consensus on switching Platelet P2Y12 Receptor – Inhibiting therapies. Circulation. 2017, 136: 1955–1975. doi: 10.1161 / CIRCULAtIonAHA.117.031 164.
(check this in PDF content)
12
Alexopoulos D, Xanthopoulou I, Deftereos s et al. In‑hospital switching of oral P2Y12 inhibitor treat‑ ment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short‑term outcome. Am Heart J, 2014, 167: 68–76.e2. doi: 10.1016 / j. ahj.2013.10.010.
(check this in PDF content)
13
Clemmensen P, Grieco n, Ince H et al. MULtIPRAC study investigators. MULtInational non‑interven‑ tional study of patients with st‑segment eleva‑ tion myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopido‑ grel: the european MULtIPRAC Registry. eur Heart J Acute Cardiovasc Care, 2015, 4: 220–229. doi: 10.1177 / 2 0 4 8 872 614 5474 4 9.
(check this in PDF content)
14
Bagai A, Peterson eD, Honeycutt e et al. In‑hospital switching between adenosine diphosphate recep‑ tor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary prac‑ tice from the tRAnsLAteACs study. eur Heart J Acute Cardiovasc Care, 2015, 4: 499–508. doi: 10.1177 / 2048872614564082.
(check this in PDF content)
15
schiele F, Puymirat e, Bonello L et al. switching between thienopyridines in patients with acute myocardial infarction and quality of care. open Heart, 2016, 3: e000384. doi: 10.1136 / openhrt‑2015–000384.
(check this in PDF content)
16
Luca L, Leonardi s, Cavallini C et al. eYesHot Investigators. Contemporary antithrombotic strate‑ gies in patients with acute coronary syndrome admit‑ ted to cardiac care units in Italy: the eYesHot study. eur Heart J Acute Cardiovasc Care, 2015, 4: 441–452. doi: 10.1177 / 2048872614560505.
(check this in PDF content)
17
Bagai A, Wang Y, Wang tY et al. In‑hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percu‑ taneous coronary intervention: insights into contem‑ porary practice from the national Cardiovascular Data Registry. Circ Cardiovasc Interv, 2014, 7: 585–593. doi: 10.1161 / CIRCInteRVentIons.114.001555.
(check this in PDF content)
18
Zettler Me, Peterson eD, McCoy LA et al. tRAnsLAte‑ ACs Investigators. switching of adenosine diphos‑ phate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of treatment Patterns and events after Acute Coronary syndrome (tRAnsLAte‑ACs) observational study. Am Heart J, 2017, 183: 62–68. doi: 10.1016 / j.ahj.2016.10.006.
(check this in PDF content)
19
Luca L, D’Ascenzo F, Musumeci G et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary inter‑ vention: the sCoPe registry. euroIntervention, 2017, 13: 459–466. doi: 10.4244 / eIJD‑17–00092.
(check this in PDF content)
20
Cuisset t, Deharo P, Quilici J et al. Benefit of switch‑ ing dual antiplatelet therapy after acute coronary syndrome: the toPIC (timing of Platelet Inhibition After Acute Coronary syndrome) randomized study. eur Heart J, 2017 nov 1, 38 (41 ): 3070–3078. doi: 10.1093 / eurheartj / ehx175.
(check this in PDF content)
21
sibbing D, Aradi D, Jacobshagen C et al. Guided de‑ escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (tRoPICAL‑ACs): a randomised, open‑label, multicentre trial. Lancet, 2017, 390: 1747– 1757. doi: 10.1016 / s0140–6736 (17) 32155–4.
(check this in PDF content)
22
Motovska Z, Hlinomaz o, Miklik R et al. Prasugrel versus ticagrelor in Patients with Acute Myocardial Infarction treated with Primary Percutaneous Coronary Intervention. Multicenter Randomized PRAGUe‑18 study. Circulation, 2016 nov 22, 134 (21 ): 1603– 1612.
(check this in PDF content)
23
Motovska Z, Hlinomaz o, Kala P et al. 1‑Year outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction treated With Prasugrel Versus ticagrelor. J Am Coll Cardiol, 2018 Jan 30, 71 (4): 371– 381. doi: 10.1016 / j.jacc.2017.11.008.
(check this in PDF content)
24
Bundhun PK, shi J‑X, Huang F. Head to head com‑ parison of Prasugrel versus ticagrelor in patients with acute coronary syndrome: a systematic review and meta‑analysis of randomized trials. BMC Pharmacology and toxicology, 2017, 18: 80. doi 10.1186 / s40360‑017‑0189– 7.
(check this in PDF content)
25
sakurai R, Burazor I, Bonneau Hn, Kaneda H. Head‑ to‑head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary inter‑ vention: A meta‑analysis of randomized controlled trials. J Interv Cardiol, 2017 oct, 30 (5): 4 57–464. doi: 1 0 . 1111 / joic.12416.
(check this in PDF content)
26
Larmore C, effron MB, Molife C et al. «Real‑world» comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percu‑ taneous coronary intervention in the United states, Catheter. Cardiovasc. Interv., 2016, 88 (4): 535–544.
(check this in PDF content)
27
Danchin n, Lettino M, Zeymer U et al. Use, patient selection and outcomes of P2Y12 receptor inhibi‑ tor treatment in patients with steMI based on contemporary european registries. eur Heart J Cardiovasc Pharmacother, 2016, 2: 152–167. doi: 10.1093 / ehjcvp / pvw003.
(check this in PDF content)
28
Rezaei ss, Geroldinger A, Heinze G et al. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nation‑ wide long‑termregistry analysis from 2009 to 2014. International Journal of Cardiology, 2017, 235: 61–66.
(check this in PDF content)
29
Alexopoulos D, Xanthopoulou I, Deftereos s et al. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percuta‑ neous coronary intervention: one‑year outcomes from the Greek AntiPlatelet Registry (GRAPe). J
(check this in PDF content)